OncoBEAM™ KRAS

  • The OncoBEAM™ KRAS test is a bead-based digital PCR approach (also called BEAMing Digital PCR) allowing for the detection of up to 10 different mutations within the KRAS gene from one single sample.
  • Mutations covered:
    G12S, G12R, G12C, G12D, G12A, G12V, G13D, Q61L, Q61H

Documents

All
  • All
  • Brochure
Documents

V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) is a member of the RAS family of protein kinases playing a key role within the MAPK signaling pathway.

KRAS is involved in important cell functions including cellular growth, proliferation and differentiation. KRAS mutations are generally correlated with poor prognosis and treatment response (1-3). KRAS mutation status has been shown to be predictive for response to anti-EGFR therapies in colorectal cancer patients (4). In addition, recent studies have shown that KRAS mutations are involved in secondary resistance to anti-EGFR therapies  in colorectal cancers (5-6).

 

* FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

BACK TO LIST

Mutations

Mutations

Clinical Relevance

Clinical Relevance

Cancer Relevance

  • Colorectal cancer
  • NSCLC
  • Pancreatic cancer

Drug Relevance

  • Anti-EGFR therapies including cetuximab (Erbitux®) and panitumumab (Vectibix®)
  • EGFR small molecule inhibitors inlcuding gefitinib (Iressa®) and erlotinib (Tarceva®)
Test Details

Test Details

Turn around times

  • Batch analysis <4 weeks
  • Single samples < 10 days

Sample Requirements

  • Serum/Plasma
    ≥ 2 ml
  • Whole blood
    10 ml
  • FFPE/Frozen Tissue
    3 sections at 5 μm
References

References

  1. Uberall I et al. (2008) Exp Mol Pathol. 84:79-89
  2. Cappuzzo F et al. (2008) Br J Cancer 99:83-9
  3. Eberhard DA et al. (2005) J Clin Oncol. 23:5900-9
  4. Ruzzo A et al. (2010) Curr Cancer Drug Targets  10(1):68-79
  5. Misale S et al. (2012) Nature 486(7404):532-6
  6. Diaz LA et al. (2012) Nature 486(7404):537-40
Create Pdf